CPT code 17274 covers the destruction of a malignant skin lesion measuring 3.1 cm to 4.0 cm in diameter using methods such as chemosurgery, cryosurgery, electrosurgery, or other destructive techniques. This procedure code is used in outpatient settings and is important for documenting and billing definitive, local tumor control when excision is not performed or feasible. Nationally, accurate use of the code affects clinical documentation, payment consistency, and quality measurement for skin cancer management.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines which payers recognize the code, typical reimbursement considerations, and common billing modifiers used in practice. It also situates the code within clinical workflows—primarily dermatology and surgical outpatient services where lesion-specific destructive procedures are performed.

Readers will find benchmarks for utilization and reimbursement patterns, an explanation of clinical scenarios where this code applies, and summaries of payer policy features relevant to coverage and prior authorization. Data gaps in the input are noted as "Data not available in the input." This summary is intended to support clinicians, coding professionals, and policy analysts who need a concise reference to CPT code 17274 and its role in malignant skin lesion treatment billing.